Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00253513 · OUTCOME

Incidence (Percent of Participants) With Nonrelapse Mortality (NRM) by Day 200 (Secondary Phase Only)

Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome · Source last updated 2012-06-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percent of participants
Interval / dispersion
95% Confidence Interval
Time frame
200 days

What was measured

NRM (Non relapse mortality) - death not attributed to the primary cancer.

Groups in this outcome

Treosulfan and Fludarabine Conditioning

Conditioning with Treosulfan (12 or 14 g/m2, IV for 5 days) and Fludarabine (30 mg/m2, IV for 5 days) followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treosulfan and Fludarabine Conditioning60

Reported measurements

Source class 1
Values in percent of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treosulfan and Fludarabine Conditioning5Not reported010.5Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        10.5
        value
        5
denoms
  1. counts
    1. group Id
      OG000
      value
      60
    units
    Participants
description
NRM (Non relapse mortality) - death not attributed to the primary cancer.
dispersion Type
95% Confidence Interval
groups
  1. description
    Conditioning with Treosulfan (12 or 14 g/m2, IV for 5 days) and Fludarabine (30 mg/m2, IV for 5 days) followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
    id
    OG000
    title
    Treosulfan and Fludarabine Conditioning
param Type
NUMBER
reporting Status
POSTED
time Frame
200 days
title
Incidence (Percent of Participants) With Nonrelapse Mortality (NRM) by Day 200 (Secondary Phase Only)
type
PRIMARY
unit Of Measure
percent of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice